https://orcid.org/0000-0001-8048-9587
References
- World Health Organisation. [cited 2020 Jun 3]. https://www.who.int/health-topics/tobacco#tab=tab_1.
- Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tobacco Res. 1999;1:S51–S57.
- Chenoweth MJ, Novalen M, Hawk LW, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Preventi Biomarkers. 2014;23:1773–1782.
- Berrendero F, Robledo P, Trigo MT, et al. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev. 2010;35:220–231.
- True WR, Xian H, Scherrer JF, et al. Common genetic vulnerability for nicotine and alcohol dependence in men. Archives Gen Psychiatry. 1999;56:655–661.
- Verhagen M, Kleinjan M, Engels R. A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. Pharmacogenomics. 2012;13:917–933.
- Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:12–15.
- Isola R, Zhang H, Tejwani GA, et al. Dynorphin and prodynorphin mRNA changes in the striatum during nicotine withdrawal. Synapse. 2008;62:448–455.
- Ise Y, Narita M, Nagase H, et al. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacol. 2000;151:49–54.
- Ise Y, Narita M, Nagase H, et al. Modulation of κ-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neurosci Lets. 2002;323:164–166.
- Ray R, Ruparel K, Newberg A, et al. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA. 2011;108:9268–9273.
- Levran O, Londono D, O’hara K, et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 2008;7:720–729.
- Ashenhurst JR, Bujarski S, Ray LA. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav. 2012;103:253–259.
- Albonaim A, Fazel H, Sharafshah A, et al. Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population. J Addict Dis. 2017;36:227–235.
- Roche D, Trela CJ, Argos M, et al. Lack of association between opioid-receptor genotypes and smoking cessation outcomes in a randomized, controlled naltrexone trial. Alcohol and Alcoholism. 2019;54:559–565.